VIVES is a multi-sector fund that invests in projects with a positive societal impact
Novadip was founded in 2013 as spin-off comany from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of professor and founder Dr. Denis Dufrane...
The Akkermansia company is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (BE) and the University of Wageningen (NL). It...
Founded at the end of the nineties, NeuroTECH was co-founded by Mr. Troosters and three members of UCLouvain (Prof. C. Trullemans, Prof. Cl. Veraart and Dr. J. Delbeke).
During the first years and in...
Pierre Delatte, CTO and co-founder of Cissoid:
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the commercialization...
Michel Detheux, CEO iTeos Therapeutics:
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Gael Rouvroy, CEO intoPIX:
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is